Stimcell Energetics (STME) Liabilities and Shareholders Equity (2011 - 2026)
Stimcell Energetics' (STME) quarterly Liabilities and Shareholders Equity came in at $34521.0 in Q1 2026, up 101.76% year-on-year from $17110.0 in Q1 2025, and down 34.05% quarter-over-quarter from $52345.0 in Q4 2025.
Stimcell Energetics (STME) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Stimcell Energetics' Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $34521.0 for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 101.76% year-over-year to $34521.0 in Q1 2026; TTM through Feb 2026 was $124475.0, a 0.4% change from a year earlier, with the FY2025 full-year figure at $21222.0, down 53.99% from the prior year.
- Liabilities and Shareholders Equity eased to $34521.0 in Q1 2026 per STME's latest filing, from $52345.0 in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $103270.0 in Q2 2023 and bottomed at $13896.0 in Q1 2023.
- The 5-year median for Liabilities and Shareholders Equity is $34521.0 (2026), against an average of $40093.2.
- Across the five-year window, Liabilities and Shareholders Equity surged 489.51% in 2024 and tumbled 79.11% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $24022.0 in 2022, then retreated by 4.74% to $22883.0 in 2023, then jumped by 67.57% to $38346.0 in 2024, then soared by 36.51% to $52345.0 in 2025, then tumbled by 34.05% to $34521.0 in 2026.
- Per Business Quant, the three latest STME Liabilities and Shareholders Equity figures stand at $34521.0 (Q1 2026), $52345.0 (Q4 2025), and $16387.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 6.63 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 31.92 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 10.46 Bn |
| 10 | Stimcell Energetics | 5.85 Mn | 5.84 Mn | - | 34,521.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 34,521.00 |
| Nov 30, 2025 | 52,345.00 |
| Aug 31, 2025 | 16,387.00 |
| May 31, 2025 | 21,222.00 |
| Feb 28, 2025 | 17,110.00 |
| Nov 30, 2024 | 38,346.00 |
| Aug 31, 2024 | 22,397.00 |
| May 31, 2024 | 46,122.00 |
| Feb 29, 2024 | 81,918.00 |
| Nov 30, 2023 | 22,883.00 |
| Aug 31, 2023 | 62,326.00 |
| May 31, 2023 | 103,270.00 |
| Feb 28, 2023 | 13,896.00 |
| Nov 30, 2022 | 24,022.00 |
| Aug 31, 2022 | 28,576.00 |
| May 31, 2022 | 41,344.00 |
| Feb 28, 2022 | 54,900.00 |
| Nov 30, 2021 | 72,574.00 |
| Aug 31, 2021 | 101,896.00 |
| May 31, 2021 | 52,242.00 |